Adlai Nortye wins Australian HREC approval for AN4035 phase 1 trial - ANL News | RalliesAdlai Nortye wins Australian HREC approval for AN4035 phase 1 trial
A
ANL• Australian approval for Phase I study
- Adlai Nortye received Australian HREC clearance for a Phase I trial of AN4035, a CEACAM5-targeting pan-RAS(ON) inhibitor antibody-drug conjugate.
- The company also filed a Clinical Trial Notification with Australia’s TGA to start the study.
- First patient dosing is expected in 2H 2026; IND filings with the U.S. FDA and China’s NMPA are in progress.
